BLOG
Blog
Inside The Altascientist: Nonclinical Dermal Study Considerations
Issue 39 of The Altascientist explores challenges and considerations for dermal studies, candidate selection for transdermal drug delivery systems (TDDS), and more
Blog
My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference
Martin Turcotte, Scientific Liaison, Altasciences, recaps two notable talks on cell and gene therapy from the 2024 Boston Society Cell and Gene Therapy Conference.
Blog
Optimizing for Success: How Sponsors Can Overcome the Challenges in Early-Phase Drug Development
Early-phase drug development is a complex process. Discover how Altasciences, as an integrated CRO/CDMO, alleviates the challenges and reduces risks.
Blog
Inside The Altascientist: Unpacking the Bioanalytical and Regulatory Considerations for Antisense Oligonucleotide (ASO) Studies
This issue of The Altascientist explores the necessary regulatory and bioanalytical considerations for using ASOs in therapeutic drug development. Listen now!
Blog
Five Promising Treatment Areas in Early-Phase Drug Development in 2024
Explore emerging areas of drugs from psychedelics and gene therapy, oligonucleotides to GLP-1RA for metabolic disorders.
Blog
Inside The Altascientist: The Benefits of PCR for Your Gene Therapy Programs
Issue 37 of The Altascientist reveals the advantages of Altasciences’ PCR capabilities, and how to integrate them into your gene therapy studies.